Proactive Investors - Run By Investors For Investors
Why invest in BVC?
BATM Advanced Communications Ltd: THE INVESTMENT CASE

BATM Advanced Communications seeing the rewards from investment and new product launches

It also confirmed it expects growth for the full-year to be in line with market expectations
BATM Advanced Communications seeing the rewards from investment and new product launches
BATM has a thriving cyber security operation

BATM Advanced Communications Limited (LON:BVC), a provider of real-time technology for networking and lab systems, is reaping the rewards of sustained investment and product launches.

A strong second half performance in 2017 prompted the company in February 2018 to advise the market to raise its expectations in terms of revenue and underlying earnings (EBITDA).

The group said it expects revenue for 2017 to be around US$106mln, which would represent year-on-year growth of 17%.

The increase in revenue was driven by growth in both of the group's divisions, BATM said.

EBITDA is expected to be around US$7.0mln, up from US$2.8mln in 2017, although the group pointed out that both the 2016 and 2017 EBITDA figures were inflated by profits from property disposals.

In 2017, the EBITDA figure was boosted by roughly US$5.6mln of profits from a property disposal, compared to the preceding year when it pocketed a profit of around US$2.8mln from another property disposal.

The business is divided into two parts, both of which are growing

The group operates two divisions: bio-medical (which includes diagnostics and accounts for around 58% of total revenues) and the networking and cyber division, which accounts for 42%.

The bio-medical arm is split into three further sub-units: distribution operation, eco-med (waste treatment) and sterilisation and diagnostics. The networking and cyber division is just that and does what it says on the tin.

In 2017, the networking & cyber division generated significantly better-than-expected sales largely due to growth in the group's existing information and communications technology services and solutions business as well as its success in implementing its strategy to leverage the telecom industry transition from hardware to network function virtualisation (NFV) and software-defined networking (SDN).

Revenue growth in the Bio-Medical division was driven by stronger sales in the distribution unit, mostly based on diagnostic and molecular biology products and services.

Strong finish to 2017 bodes well for current trading

“The importance of this update, in our view, is what it implies for the trading performance going into the current year, in particular higher revenues from recent published contract success across the group with positive operating leverage beginning to come through,” said Shore Capital, the company’s house broker.

The broker has upgraded its expectations for 2018 accordingly, noting that “investors will welcome this significant trading improvement after the last few years of strategic development from BATM”.

It has bumped up its revenue forecast by 9% to US$110mln while its underlying earnings (EBTIDA) estimate has been increased from US$2.8mln to US$3.9mln – an increase of 39%.

Adjusted earnings per share are now forecast to be 0.25 cents versus 0.07 cents previously.

“With BATM’s intellectual property set configured to tackle real world challenges in its specialist markets, we believe that the scope for further revenue and profit improvement is significant,” the broker said.

View full BVC profile View Profile

BATM Advanced Communications Ltd Timeline

Related Articles

February 19 2018
It also confirmed it expects growth for the full-year to be in line with market expectations

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use